Table 5.

Clinical studies related to the autophagy of pancreatic cancer between 2013 and 2023.

Study	ClinicalTrials.gov Identifier	Official title	Time	Country	Design	No. of patients	Conditions	Intervention		Phase	Primary purpose
								Treatment group	Comparison group
1	NCT04386057	LY3214996 +/- HCQ in Pancreatic Cancer	2020.12.13- 2023.12. 19	United States	Interventional	52	Pancreatic Cancer Advanced Cancer	Drug: Hydroxychloroquine Sulfate Drug: LY3214996	LY3214996	Phase 2	Treatment
2	NCT04132505	Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant metastatic Pancreatic Cancer	2019.10. 22 -2023.12.31	United States	Interventional	39	Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8	Drug: Binimetinib Drug: Hydroxychloroquine	binimetinib	Phase 1	Treatment
3	NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer	2020.9.14 -2024.8.14	United States	Interventional	21	Advanced Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Drug: Gemcitabine Drug: Hydroxychloroquine Drug: Nab-paclitaxel	Drug: Nab-paclitaxel Drug: Paricalcitol	Phase 2	Treatment
4	NCT01978184	Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine	2013.11-2018.02.28	United States	Interventional	104	Pancreatic Cancer	Drug: gemcitabine Drug: abraxane Drug: hydroxychloroquine	Gemcitabine	Phase 2	Treatment
5	NCTNCT01506973	A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to inhibit Autophagy in Pancreatic Cancer	2011.12-2022.03	United States	Interventional	119	Advanced Adenocarcinoma Metastatic Adenocarcinoma	Drug: Hydroxychloroquine (HCQ) Drug: Gemcitabine Drug: Abraxane	Drug: Gemcitabine Drug: Abraxane	Phase1 Phase 2	Treatment